Valeant Pharmaceuticals company information, Employees & Contact Information

Valeant Will Become Bausch Health Companies Inc. PR Newswire

Valeant Shows the Perils of Fantasy Numbers (Published 2015) The New York Times

Valeant Announces New U.S. Fulfillment Agreements with Walgreens; Plans to Further Extend Distribution to Independent Pharmacies Walgreens Boots Alliance

Bausch Health to pay $45M to settle US charges over Valeant-era accounting BioPharma Dive

The rise and fall of Valeant Pharmaceuticals CBC

Two Are Charged In Fraud And Kickback Scheme Against Valeant Pharmaceuticals Forbes

Inside the Valeant Scandal The New Yorker

$45.4 Million Fair Fund for Eligible Valeant Stock and Bond Holders Claim Depot

Valeant gets a new name to shed its scandals, but will it work? MarketWatch

Valeant Pharmaceuticals to Change Its Name to Bausch Health - WSJ The Wall Street Journal

Valeant’s Accounting Error a Warning Sign of Bigger Problems (Published 2016) The New York Times

Valeant Agrees To Sell Obagi Medical Products Business PR Newswire

Valeant Pharmaceuticals' Prescription For Disaster Forbes

Valeant: Why Moneyball Failed in the Pharmaceutical Industry The New Yorker

Valeant Pharmaceuticals Picks Joseph Papa, Perrigo Chief, as C.E.O. (Published 2016) The New York Times

Valeant’s High-Price Drug Strategy (Published 2015) The New York Times

Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers (Published 2015) The New York Times

Valeant’s Shares Fall on Report’s Fraud Claim (Published 2015) The New York Times

Valeant Promised Price Breaks on Drugs. Heart Hospitals Are Still Waiting. (Published 2016) The New York Times

Valeant Makes Distribution Deal With Walgreens (Published 2015) The New York Times

Valeant Drops Philidor Mail-Order Pharmacy (Published 2015) The New York Times

Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion PR Newswire

Valeant, Distancing Itself From Its Past, Will Change Its Name to Bausch Health (Published 2018) The New York Times

How Valeant Cashed In Twice on Higher Drug Prices (Published 2016) The New York Times

Valeant Pharmaceuticals to Make Sweeping Changes to Board The Wall Street Journal

Valeant Announces Sale of iNova Pharmaceuticals for $930 Million PR Newswire

Valeant under investigation by US regulators BBC

Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal PR Newswire

Valeant Says It Will Restate Earnings After Board Review Bloomberg.com

Valeant: The harder they fall Financial Times

Valeant ‘made mistakes’ in raising drug prices, outgoing CEO tells lawmakers statnews.com

Valeant Pharmaceuticals Chief Returns From Medical Leave (Published 2016) The New York Times

Valeant Under Investigation for Its Drug Pricing Practices (Published 2015) The New York Times

Valeant Pharmaceuticals' Dizzying Fall From Investors' Good Graces Forbes

Valeant Pharmaceuticals blasted by U.S. lawmakers over drug price hikes CBC

Valeant Pharmaceuticals to sell iNova business for $930m Pharmaceutical Technology

A Shake-Up at Valeant Signals the End of an Era (Published 2016) The New York Times

Valeant CEO Faces Hostile Congress, Regrets Drug Price Hikes NBC News

Bill Ackman’s Enigmatic Approach to Valeant Pharmaceuticals (Published 2015) The New York Times

The Valeant Meltdown and Wall Street’s Major Drug Problem Vanity Fair

Valeant Pharmaceuticals Renews CeraVe® Partnership with USA Swimming as Exclusive Skincare Sponsor PR Newswire

VALEANT: How A Canadian Pharmaceutical Company Could Destroy The Industry As We Know It businessinsider.com

Valeant Pharmaceuticals and the dark side of capitalism marketplace.org

Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P. PR Newswire

Valeant uses rare accounting maneuver for acquisitions that cushions income MarketWatch

Valeant Pharmaceuticals Confirms C.E.O. Is on Medical Leave (Published 2015) The New York Times

Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection PR Newswire

Valeant Pharmaceuticals' Stock in 4 Charts The Motley Fool

Valeant’s 2016 Has Been All Pain, No Gain Amid Record Stock Drop Bloomberg.com

Valeant Pharmaceuticals names new CFO amid turmoil USA Today

Boss axed at controversy-hit Valeant Pharmaceuticals BBC

Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications PR Newswire

Valeant pays $54 million to settle U.S. kickback, fraud claims Reuters

Munger: Valeant Pharmaceuticals turned out to be a 'sewer' CNBC

How Bill Ackman Lost His Whole $4 Billion in Valeant—and Then Some Fortune

Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount PR Newswire

William Ackman’s Pershing Square Sold Stake in Valeant The Wall Street Journal

Valeant Files Much Delayed Annual Earnings Saying Its "Cured" of Default Fortune

Billionaire Bill Ackman Sells Disastrous Valeant Investment After Nearly $4 Billion Loss Forbes

The ‘Short’ Who Sank Valeant Stock The Wall Street Journal

Valeant Bet Was a ‘Huge Mistake,’ Hedge Fund Chief Ackman Says (Published 2017) The New York Times

Valeant Pharmaceuticals’ Novel Business Approach Made It a Wall Street Darling — Then a Pariah New York Magazine

Maker of Addyi, ‘Female Viagra’ Drug, Being Sold to Valeant for $1 Billion (Published 2015) The New York Times

The rise and fall of Valeant businessinsider.com

Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis PR Newswire

Ackman Sells Valeant Stake After at Least $2.8 Billion Loss Bloomberg.com

How 4 drug companies rapidly raised prices on life-saving drugs Los Angeles Times

Lawmakers accuse Valeant of stonewalling their investigation statnews.com

Michael Pearson Says Valeant Pharmaceuticals Will Survive, Short-Term Earnings Will Drop Forbes

Ackman's Pershing Square sells Valeant stake, takes $3 billion loss Reuters

Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Still A Gamble US News Money

Billionaire John Paulson joins Valeant Pharmaceuticals board upi.com

Valeant: A timeline of the big Pharma scandal Fortune

Valeant Pharmaceuticals' Philidor Rx Unit Says It Has A Right To Buy R&O Pharmacy Forbes

Valeant Pharmaceuticals Stock Has Plunged 86% in 2016. When Will the Nightmare End? The Motley Fool

Ex-Valeant CEO might have earned a $2.66B stock payoff. Today? It's zero Fierce Pharma

What Caused Valeant’s Epic 90% Plunge Fortune

At least one Valeant investor is standing tall amid the carnage USA Today

Johnson & Johnson sold us the talc product, Valeant CEO says. Now it should cover our legal defense Fierce Pharma

Valeant to change name as part of image rebuild CBC

Valeant recalls a half-million bottles of generic Librax Fierce Pharma

The Single Most Important Metric to Determine if Valeant Pharmaceuticals Is a Buy The Motley Fool

Is Valeant Pharmaceuticals (NYSE: VRX) the New Enron? Money Morning

Valeant Pharmaceuticals International: Perspective on financial statement issues businessjournalism.org

Why Valeant Pharmaceuticals Intl. Inc. Crashed in 2015 The Motley Fool

Valeant Pharmaceuticals' Prescription For Disaster Forbes India

Valeant under scrutiny for doubling price of assisted suicide drug sold in U.S. CBC

Valeant Pharmaceuticals to clean up its name by changing it: William Ackman The Indian Express

Valeant Pharmaceuticals CEO J. Michael Pearson to step down Global News

Aussie John Hempton beat Wall Street royalty on Valeant AFR